Evidence map›Paper›PMID 29867083›Full record

ArticleScientific reports2018

Luteolin attenuates Wnt signaling via upregulation of FZD6 to suppress prostate cancer stemness revealed by comparative proteomics.

Kun Han, Tingyuan Lang, Zhiqi Zhang, Yi Zhang, Yongning Sun, Zan Shen, Roger W Beuerman, Lei Zhou, Daliu Min

Open access · goldAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 61 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Construction of Fzd6Molecular biology reports · 2022
    Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Kun HanDepartment of Medical Oncology, The Affiliated 6th People's Hospital of Shanghai Jiaotong University, Shanghai, 200233, China.
Tingyuan LangKey Laboratory of Clinical Laboratory Diagnostics (Ministry of Education), College of Laboratory Medicine, Chongqing Medical University, Chongqing, 400016, China.
Zhiqi ZhangDepartment of Medical Oncology, The Affiliated 6th People's Hospital of Shanghai Jiaotong University, Shanghai, 200233, China.
Yi ZhangKey Laboratory of Clinical Laboratory Diagnostics (Ministry of Education), College of Laboratory Medicine, Chongqing Medical University, Chongqing, 400016, China.
Yongning SunDepartment of Medical Oncology, The Affiliated 6th People's Hospital of Shanghai Jiaotong University, Shanghai, 200233, China.
Zan ShenDepartment of Medical Oncology, The Affiliated 6th People's Hospital of Shanghai Jiaotong University, Shanghai, 200233, China.
Roger W BeuermanSingapore Eye Research Institute, The Academia, 20 College Road, Discovery Tower level 6, Singapore, 169856, Singapore.
Lei ZhouSingapore Eye Research Institute, The Academia, 20 College Road, Discovery Tower level 6, Singapore, 169856, Singapore. zhou.lei@seri.com.sg.
Daliu MinDepartment of Medical Oncology, The Affiliated 6th People's Hospital of Shanghai Jiaotong University, Shanghai, 200233, China. doctor_mindaliu@163.com.
Chongqing Medical University · CNNational University of Singapore · SGSingapore Eye Research Institute · SG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The mechanisms underlying luteolin-induced inhibition of prostate cancer (PCa) stemness have remained elusive. Here, we report that luteolin suppresses PCa stemness through Wnt signaling by upregulation of FZD6 (frizzled class receptor 6). Luteolin inhibits PCa cell proliferation, migration, self-renewal as well as the expression of prostate cancer stem cell markers in vitro. Through iTRAQ-based quantitative proteomics study, we identified 208 differentially expressed proteins in luteolin-treated PC-3 cells. Subsequent mechanistic analysis revealed that luteolin inhibits Wnt signaling by transcriptional upregulation of FZD6, and thereby suppressing the stemness of PCa cells. Furthermore, we identified FZD6 as a tumor suppressor that can abolish PCa stemness. In summary, our findings demonstrate that suppression of Wnt signaling by upregulation of FZD6 is a mechanism underlying luteolin-induced inhibition of PCa stemness. Our work suggests a new therapeutic strategy against human prostate cancer caused by aberrant activation of Wnt signaling.

Indexed as

Frizzled ReceptorsGene Expression Regulation, NeoplasticHumansLuteolinMaleNeoplastic Stem CellsPC-3 CellsProstatic NeoplasmsProteomicsTumor Suppressor ProteinsUp-RegulationWnt Signaling PathwayFrizzled ReceptorsFZD6 protein, humanLuteolinTumor Suppressor Proteins

Identifiers

PMID29867083
PMCPMC5986741
OpenAlexW2807250734

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.